<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393963</url>
  </required_header>
  <id_info>
    <org_study_id>B2013-089</org_study_id>
    <nct_id>NCT02393963</nct_id>
  </id_info>
  <brief_title>Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty</brief_title>
  <official_title>Role of Low Dose Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty: A Randomized Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthopaedic Innovation Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orthopaedic Innovation Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, controlled trial in patients undergoing elective Total&#xD;
      Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA). The study group will receive&#xD;
      intra-articular Tranexamic Acid (TXA) while the control group will receive normal saline&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to determine if intra-articular administration of low&#xD;
      dose TXA following THA and TKA results in a clinically relevant reduction in blood loss. The&#xD;
      secondary purpose is to determine if there is an increased risk of thromboembolic phenomena&#xD;
      with the use of TXA following elective THA and TKA. The primary outcome metric will be - drop&#xD;
      in hemoglobin following surgery; secondary metrics include blood loss, transfusion rate,&#xD;
      d-dimers, troponin levels, symptomatic deep venous thrombosis (DVT) and pulmonary embolism&#xD;
      (PE), vascular events (myocardial infarction, stroke), major and minor bleeding, and death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 21, 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in hemoglobin during hospital stay</measure>
    <time_frame>routinely measured post-op day 1 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Troponin</measure>
    <time_frame>Every 6 hours for 24 hours post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Post-op day 1 and 2</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-operative blood transfusion</measure>
    <time_frame>During the first 7 days</time_frame>
    <description>documentation of blood transfusion post-operative</description>
  </other_outcome>
  <other_outcome>
    <measure>Major or minor bleeding events</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported visual disturbances</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported symptomatic DVT</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported PE</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported stroke</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intra-operative fluid balance</measure>
    <time_frame>during surgery</time_frame>
    <description>documentation of the volume of saline fluid via intravenous given to patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding sources other than the knee or hip (eg: GI bleed)</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>post-operative fluid balance</measure>
    <time_frame>within 3- 5 days of surgery</time_frame>
    <description>documentation of the volume of saline fluid via intravenous given to patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular administration of low dose Tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>DIN#: 02246365, Sandoz Canada Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium Chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with osteoarthritis&#xD;
&#xD;
          -  scheduled for elective primary unilateral THR or TKR&#xD;
&#xD;
          -  provided informed consent&#xD;
&#xD;
          -  can read, write and speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of arterial or venous thromboembolic disease (myocardial infarction,&#xD;
             symptomatic ischemic heart disease, atrial fibrillation, cerebrovascular accident,&#xD;
             deep-vein thrombosis, pulmonary embolus, or thrombogenic cardiac valvular disease or&#xD;
             rhythm disease)&#xD;
&#xD;
          -  pre-operative Hg of &lt;120 g/L&#xD;
&#xD;
          -  Known allergy to Tranexamic Acid&#xD;
&#xD;
          -  Coagulation disorder&#xD;
&#xD;
          -  Acquired disturbances of color vision&#xD;
&#xD;
          -  Hepatic insufficiency, any history of liver disease&#xD;
&#xD;
          -  Renal insufficiency (on dialysis)&#xD;
&#xD;
          -  Preoperative prophylactic use of antiplatelet or anticoagulant therapy such as&#xD;
             Clopidogrel, Warfarin, dabigatran or Rivaroxaban. This does not include low dose&#xD;
             Aspirin (81mg)&#xD;
&#xD;
          -  Patients with a history of subarachnoid hemorrhage [20]&#xD;
&#xD;
          -  Simultaneous bilateral THA or TKA&#xD;
&#xD;
          -  Any contra-indication for spinal anesthesia&#xD;
&#xD;
          -  Allergy to Celecoxib, which will be the only nonsteroidal anti-inflammatory drugs&#xD;
             (NSAID) used in the multi-modal analgesia regime.&#xD;
&#xD;
          -  Retinal vein or retinal artery occlusion&#xD;
&#xD;
          -  Female on oral contraceptive pills and/or premenopausal&#xD;
&#xD;
          -  Concurrently taking hydrochlorothiazide, desmopressin, sulbactam-ampicillin,&#xD;
             carbazochrome, ranitidine and/or nitroglycerin for the duration of the surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Turgeon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Concordia Joint Replacement Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Concordia Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

